日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial

新辅助帕博西尼联合内分泌治疗与化疗治疗ER+/HER2-乳腺癌：一项随机II期试验

期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-026-71452-6
Matikas, Alexios; Tzoras, Evangelos; Sarafidis, Michail; Sifakis, Emmanouil G; Bjöhle, Judith; Barnekow, Elin; Margolin, Sara; Isaksson-Friman, Erika; Kessler, Luisa Edman; Zouzos, Athanasios; Johansson, Hemming; Hellström, Mats; Agartz, Susanne; Grybäck, Per; Salgkamis, Dimitrios; Zerdes, Ioannis; Wang, Kang; Hartman, Johan; Acs, Balazs; Sun, Wenwen; Boyaci, Ceren; Villacampa, Guillermo; Pascual, Tomas; Gavila, Joaquin; Prat, Aleix; Perou, Charles; Brandberg, Yvonne; Bergh, Jonas; Hatschek, Thomas; Foukakis, Theodoros
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.

无菌α基序和HD结构域蛋白1（SAMHD1）表达在乳腺癌中的预后和预测意义

期刊:International Journal of Cancer
影响因子:4.7
doi:10.1002/ijc.35319
Kouvaraki Maria, Zerdes Ioannis, Sifakis Emmanouil G, Sarafidis Michail, Matikas Alexios, Tzoras Evangelos, Kjällquist Una, Stathopoulou Konstantina, Lövrot John, Alkodsi Amjad, Hartman Johan, Sotiriou Christos, Richard Francois, Hatschek Thomas, Herold Nikolas, Bergh Jonas, Rassidakis George Z, Foukakis Theodoros
肿瘤
乳腺癌
肿瘤免疫
发表日期：2025
文献求助 收藏

An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer

整合组学方法揭示了表观遗传事件如何解释和预测乳腺癌患者对新辅助化疗和贝伐单抗的反应。

期刊:Molecular Oncology
影响因子:4.5
doi:10.1002/1878-0261.13656
Fleischer, Thomas; Haugen, Mads Haugland; Ankill, Jørgen; Silwal-Pandit, Laxmi; Børresen-Dale, Anne-Lise; Hedenfalk, Ingrid; Hatschek, Thomas; Tost, Jörg; Engebraaten, Olav; Kristensen, Vessela N
肿瘤
表观遗传
乳腺癌
肿瘤免疫
发表日期：2024
文献求助 收藏

The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial

血清胸苷激酶1活性在接受新辅助治疗的HER2阳性乳腺癌中的作用：来自瑞典II期随机PREDIX HER2试验的生物标志物分析

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-023-07200-x
Zhu, Yajing; Zerdes, Ioannis; Matikas, Alexios; Cruz, Ivette Raices; Bergqvist, Mattias; Elinder, Ellinor; Bosch, Ana; Lindman, Henrik; Einbeigi, Zakaria; Andersson, Anne; Carlsson, Lena; Dreifaldt, Ann Charlotte; Isaksson-Friman, Erika; Hellstrom, Mats; Johansson, Hemming; Wang, Kang; Bergh, Jonas C S; Hatschek, Thomas; Foukakis, Theodoros
肿瘤
HER2
肿瘤免疫
信号转导
乳腺癌
RED
发表日期：2024
文献求助 收藏

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

KATHERINE 研究显示，对于 HER2 阳性乳腺癌且存在 HER2 阴性残留浸润性疾病的患者，辅助曲妥珠单抗-美坦新治疗效果良好。

期刊:NPJ Breast Cancer
影响因子:7.6
doi:10.1038/s41523-022-00477-z
Loibl, Sibylle; Huang, Chiun-Sheng; Mano, Max S; Mamounas, Eleftherios P; Geyer, Charles E Jr; Untch, Michael; Thery, Jean-Christophe; Schwaner, Ingo; Limentani, Steven; Loman, Niklas; Lübbe, Kristina; Chang, Jenny C; Hatschek, Thomas; Tesarowski, David; Song, Chunyan; Lysbet de Haas, Sanne; Boulet, Thomas; Lambertini, Chiara; Wolmark, Norman
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2022
文献求助 收藏

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial

新辅助曲妥珠单抗、帕妥珠单抗和多西他赛与曲妥珠单抗-美坦新治疗ERBB2阳性乳腺癌患者的疗效比较：一项II期随机临床试验

期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2021.1932
Hatschek, Thomas; Foukakis, Theodoros; Bjöhle, Judith; Lekberg, Tobias; Fredholm, Hanna; Elinder, Ellinor; Bosch, Ana; Pekar, Gyula; Lindman, Henrik; Schiza, Aglaia; Einbeigi, Zakaria; Adra, Jamila; Andersson, Anne; Carlsson, Lena; Dreifaldt, Ann Charlotte; Isaksson-Friman, Erika; Agartz, Susanne; Azavedo, Edward; Grybäck, Per; Hellström, Mats; Johansson, Hemming; Maes, Claudia; Zerdes, Ioannis; Hartman, Johan; Brandberg, Yvonne; Bergh, Jonas
ERBB2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2021
文献求助 收藏

Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers

蛋白质特征预测HER2阴性乳腺癌患者对新辅助化疗联合贝伐单抗治疗的反应

期刊:Jco Precision Oncology
影响因子:5.6
doi:10.1200/PO.20.00086
Haugen, Mads H; Lingjærde, Ole Christian; Hedenfalk, Ingrid; Garred, Øystein; Borgen, Elin; Loman, Niklas; Hatschek, Thomas; Børresen-Dale, Anne-Lise; Naume, Bjørn; Mills, Gordon B; Mælandsmo, Gunhild M; Engebraaten, Olav
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2021
文献求助 收藏

Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer

早期乳腺癌中PD-L1蛋白和RNA水平表达的不一致

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers13184655
Zerdes, Ioannis; Karafousia, Vaia; Mezheyeuski, Artur; Stogiannitsi, Maria; Kuiper, Raoul; Moreno Ruiz, Pablo; Rassidakis, George; Bergh, Jonas; Hatschek, Thomas; Foukakis, Theodoros; Matikas, Alexios
PD-L1
肿瘤
肿瘤免疫
乳腺癌
发表日期：2021
文献求助 收藏

Protein profiling of fine-needle aspirates reveals subtype-associated immune signatures and involvement of chemokines in breast cancer.

细针穿刺液的蛋白质谱分析揭示了亚型相关的免疫特征以及趋化因子在乳腺癌中的作用

期刊:Molecular Oncology
影响因子:4.5
doi:10.1002/1878-0261.12410
Franzén Bo, Alexeyenko Andrey, Kamali-Moghaddam Masood, Hatschek Thomas, Kanter Lena, Ramqvist Torbjörn, Kierkegaard Jonas, Masucci Giuseppe, Auer Gert, Landegren Ulf, Lewensohn Rolf
免疫/内分泌
乳腺癌
发表日期：2019
文献求助 收藏

Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer

对免疫浸润和免疫功能基因作为激素受体阳性、HER2阴性乳腺癌新辅助化疗预测标志物的动态评估

期刊:Oncoimmunology
影响因子:6.3
doi:10.1080/2162402X.2018.1466017
Matikas, Alexios; Lövrot, John; Ramberg, Anna; Eriksson, Margareta; Lindsten, Therese; Lekberg, Tobias; Hedenfalk, Ingrid; Loman, Niklas; Bergh, Jonas; Hatschek, Thomas; Erlandsson, Ann; Foukakis, Theodoros
肿瘤
HER2
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2018
文献求助 收藏